Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

被引：0
|
作者：
Lingyun Wu
Xiao Li
Jiying Su
Qi He
Xi Zhang
Chunkang Chang
Quan Pu
机构：
[1] The Sixth Hospital Affiliated to Shanghai Jiaotong University,Department of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2011年 / 137卷
关键词：
Myelodysplastic syndromes; Acute myeloid leukemia; Cytarabine; Homoharringtonine; Granulocyte colony-stimulating factor (G-CSF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1563 / 1569
页数：6
相关论文
共 50 条
  • [41] Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA trial)
    Kruszewski, M.
    Schmoor, C.
    Berg, T.
    Schittenhelm, M.
    Goetze, K.
    Kuendgen, A.
    Pabst, C.
    Ma, T.
    Frey, A.
    Moschalski, K.
    Rehman, U-U
    Jung, J.
    Duyster, J.
    Jung, M.
    Schuele, R.
    Waesch, R.
    Grishina, O.
    Lubbert, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 101 - 101
  • [42] Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)
    Luebbert, Michael
    Schmoor, Claudia
    Berg, Tobias
    Kruszewski, Michael
    Schittenhelm, Marcus Matthias
    Goetze, Katharina
    Pabst, Caroline
    Kuendgen, Andrea
    Ma, Tobias
    Frey, Anna
    Moschallski, Kevin
    Rehman, Usama-Ur
    Jung, Johannes
    Duyster, Justus
    Jung, Manfred
    Schuele, Roland
    Waesch, Ralph
    Grishina, Olga
    BLOOD, 2022, 140 : 9087 - 9088
  • [43] The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study
    Yang, Li
    Liu, Ligen
    Zhao, Limin
    Lu, Yingting
    Zhang, Jing
    Sun, Lihua
    BLOOD, 2019, 134
  • [44] Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
    Luebbert, Michael
    Suciu, Stefan
    Baila, Liliana
    Ruter, Bjorn Hans
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Beeldens, Filip
    Muus, Petra
    Pfluger, Karl-Heinz
    Coens, Corneel
    Hagemeijer, Anne
    Schaefer, Hans Eckart
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 1987 - 1996
  • [45] 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Pagel, JM
    Appelbaum, FR
    Sandmaier, BM
    Rajendran, JG
    Gooley, T
    Fisher, DR
    Nemecek, E
    Gopal, AK
    Maris, MB
    Ruffner, K
    Matthews, DC
    Deeg, HJ
    Maloney, DG
    Martin, PJ
    Storb, R
    BLOOD, 2005, 106 (11) : 119A - 119A
  • [46] Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study)
    Niederwieser, D.
    Becker, C.
    Krahl, R.
    Al-Ali, H.
    Lange, T.
    Gerhardt, A.
    Schulze, A.
    Haehling, D.
    Schulze, M.
    Freund, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation
    Abboud, Camille, Sr.
    Borthakur, Gautam
    Solomon, Scott R.
    Burris, Howard A., Sr.
    Bradley, Terrence
    Zaucha, Jan Maciej, Sr.
    Lech-Maranda, Ewa
    Brzozka, Krzysztof
    Rzymski, Tomasz
    Littlewood, Peter
    Mouhayar, Elie
    Shamsili, Setareh
    Angelosanto, Noemi
    BLOOD, 2021, 138
  • [48] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
    Heidel, Florian
    Cortes, Jorge
    Ruecker, Frank G.
    Aulitzky, Walter
    Letvak, Laurie
    Kindler, Thomas
    Huber, Christoph
    Doehner, Hartmut
    Kantarjian, Hagop
    Fischer, Thomas
    CANCER, 2007, 109 (05) : 907 - 914
  • [49] Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.
    Heidel, F
    Cortes, J
    Ruecker, F
    Kaufmann, M
    Aulitzky, W
    Letvak, L
    Kindler, T
    Huber, C
    Dohner, H
    Kantarjian, H
    Fischer, T
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [50] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Kurtulus, Sema
    Makofske, Jessica
    Liao, Serena
    Mohammed, Anisa
    Sabatos-Peyton, Catherine A.
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    BLOOD, 2020, 136
12345